4B-0601 is under clinical development by 4B Technologies (Suzhou) and currently in Phase II for Amyotrophic Lateral Sclerosis. According to GlobalData, Phase II drugs for Amyotrophic Lateral Sclerosis have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 4B-0601’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
4B-0601 overview
FB-1006 is under development for the treatment of amyotrophic lateral sclerosis (ALS). It is being developed based on artificial intelligence technology.
4B Technologies (Suzhou) overview
4B Technologies (Suzhou) develops a new drug for the treatment of neurogenerative disease and nerve damage. It is headquartered in Jining City, Shandong, China.
For a complete picture of 4B-0601’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.